{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:10:59Z","timestamp":1761664259431,"version":"build-2065373602"},"reference-count":23,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: The COVID-19 pandemic is an ongoing public health emergency. Patients with chronic diseases are at greater risk for complications and poor outcomes. The objective of this study was to investigate the liver function abnormalities and clinical outcomes in patients with COVID-19 and chronic hepatitis C. Materials and Methods: This retrospective, single-center study was conducted on a cohort of 126 patients with a history of hepatitis C, confirmed with COVID-19 between 01 April 2020 and 30 December 2020. Several clinical outcomes were compared between patients with active and non-active HCV infection, and the risks of liver impairment and all-cause mortality in active HCV patients were analyzed using a multivariate logistic regression model. Results: Among 1057 patients under follow-up for chronic HCV infection, 126 (11.9%) were confirmed with COVID-19; of these, 95 (75.4%) were under treatment or achieved SVR, while in the other 31 (24.6%), we found active HCV replication. There was a significantly higher proportion of severe COVID-19 cases in the active HCV group as compared to the non-active HCV group (32.2 vs. 7.3%, p &lt; 0.001). Multivariate analysis showed that age, sex, alanine aminotransferase, C-reactive protein, procalcitonin, and HCV viral load were significant independent risk factors for liver impairment and all-cause mortality. The length of stay in hospital and intensive care unit for COVID-19 was significantly higher in patients with active HCV infection (p-value &lt; 0.001), and a higher proportion of these patients required mechanical ventilation. Conclusions: Active HCV infection is an independent risk factor for all-cause mortality in COVID-19 patients.<\/jats:p>","DOI":"10.3390\/medicina57060597","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T03:48:08Z","timestamp":1623296888000},"page":"597","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Liver Impairment and Hematological Changes in Patients with Chronic Hepatitis C and COVID-19: A Retrospective Study after One Year of Pandemic"],"prefix":"10.3390","volume":"57","author":[{"given":"Bianca","family":"Cerbu","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stelian","family":"Pantea","sequence":"additional","affiliation":[{"name":"Surgical Clinic 2 Department, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4711-4315","authenticated-orcid":false,"given":"Felix","family":"Bratosin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9234-5767","authenticated-orcid":false,"given":"Iulia","family":"Vidican","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirela","family":"Turaiche","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7469-6755","authenticated-orcid":false,"given":"Stefan","family":"Frent","sequence":"additional","affiliation":[{"name":"Center for Research and Innovation in Precision Medicine of Respiratory Diseases, Department of Pulmonology, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ema","family":"Borsi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\u2014Hematology, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iosif","family":"Marincu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (WHO) (2020, December 04). Situation Reports December 2020. Available online: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus2019\/situation-reports."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMc2010419","article-title":"Clinical characteristics of Covid-19 in New York city","volume":"382","author":"Goyal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43066-021-00082-y","article-title":"The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced","volume":"11","author":"Vitiello","year":"2021","journal-title":"Egypt. Liver J."},{"key":"ref_4","unstructured":"European Centre for Disease Prevention and Control (2020). Hepatitis C. Annual Epidemiological Report for 2018, ECDC."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1016\/j.dld.2014.09.023","article-title":"Epidemiology of hepatitis C in Europe","volume":"46","author":"Negro","year":"2014","journal-title":"Dig. Liver Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cmi.2020.01.014","article-title":"Elimination of hepatitis C in Europe: Can WHO targets be achieved?","volume":"26","author":"Lombardi","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Fu, Y., Zhu, R., Bai, T., Han, P., He, Q., Jing, M., Xiong, X., Zhao, X., Quan, R., and Chen, C. (2020). Clinical features of COVID-19-infected patients with elevated liver biochemistries: A multicenter, retrospective study. Hepatology.","DOI":"10.1002\/hep.31446"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/hep.31487","article-title":"Abnormal Liver Tests in COVID-19: A Retrospective Observa-tional Cohort Study of 1,827 Patients in a Major US Hospital Network","volume":"72","author":"Hundt","year":"2020","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"S\u0142omka, A., Kowalewski, M., and \u017bekanowska, E. (2020). Coronavirus Disease 2019 (COVID\u201319): A Short Review on Hematological Manifestations. Pathogens, 9.","DOI":"10.3390\/pathogens9060493"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1111\/liv.14455","article-title":"Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China","volume":"40","author":"Zhang","year":"2020","journal-title":"Liver Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3748\/wjg.v27.i5.377","article-title":"Liver injury in the era of COVID-19","volume":"27","author":"Michalak","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41575-021-00426-4","article-title":"COVID-19 and liver disease: Mechanistic and clinical perspectives","volume":"18","author":"Marjot","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1128\/JVI.02356-06","article-title":"Scavenger Receptor BI and BII Expression Levels Modulate Hepatitis C Virus Infectivity","volume":"81","author":"Grove","year":"2007","journal-title":"J. Virol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues","volume":"181","author":"Ziegler","year":"2020","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Rabi, F.A., Al Zoubi, M.S., Kasasbeh, G.A., Salameh, D.M., and Al-Nasser, A.D. (2020). SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far. Pathogens, 9.","DOI":"10.3390\/pathogens9030231"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Neerukonda, S.N., and Katneni, U. (2020). A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions. Pathogens, 9.","DOI":"10.20944\/preprints202005.0204.v1"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Chai, X., Hu, L., Zhang, Y., and Han, W. (2020). Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infec-tion. bioRxiv.","DOI":"10.1101\/2020.02.03.931766"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00204-020-02734-1","article-title":"COVID-19 and drug-induced liver injury: A problem of plenty or a petty point?","volume":"94","author":"Boeckmans","year":"2020","journal-title":"Arch. Toxicol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1093\/cid\/ciz732","article-title":"High Rates of Drug-induced Liver Injury in People Living with HIV Coinfected With Tuberculosis (TB) Irrespective of Antiretroviral Therapy Timing During Antituberculosis Treatment: Results From the Starting Antiretroviral Therapy at Three Points in TB Trial","volume":"70","author":"Naidoo","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/liv.14435","article-title":"Liver injury during highly pathogenic human coronavirus infections","volume":"40","author":"Xu","year":"2020","journal-title":"Liver Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2020.05.013","article-title":"High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry","volume":"73","author":"Moon","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/gutjnl-2020-322118","article-title":"Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: Multicentre matched cohort","volume":"70","author":"Bajaj","year":"2021","journal-title":"Gut"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/MEG.0000000000001742","article-title":"Chronic liver disease is not associated with severity or mortality in Coronavirus dis-ease 2019 (COVID-19): A pooled analysis","volume":"33","author":"Lippi","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/6\/597\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:12:45Z","timestamp":1760163165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/6\/597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["medicina57060597"],"URL":"https:\/\/doi.org\/10.3390\/medicina57060597","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2021,6,10]]}}}